MARKET

HSTO

HSTO

Conatus Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7927
-0.0173
-2.14%
Closed 16:00 09/24 EDT
OPEN
0.8200
PREV CLOSE
0.8100
HIGH
0.8277
LOW
0.7701
VOLUME
192.53K
TURNOVER
--
52 WEEK HIGH
2.410
52 WEEK LOW
0.7428
MARKET CAP
33.08M
P/E (TTM)
-1.0484
1D
5D
1M
3M
1Y
5Y
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Rich...
GlobeNewswire · 08/31 20:05
HC Wainwright & Co. Initiates Coverage On Histogen with Buy Rating, Announces Price Target of $2.4
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Histogen (NASDAQ:HSTO) with a Buy rating and announces Price Target of $2.4.
Benzinga · 08/30 10:18
--HC Wainwright Starts Histogen at Buy With $2.40 Price Target
MT Newswires · 08/30 07:58
BRIEF-Histogen Inc - Received Letter From Nasdaq Indicating Co Did Not Meet Minimum Bid Price Of $1 Per Share Required For Continued Listing
reuters.com · 08/20 20:33
Histogen Says Received Letter From Nasdaq Indicating Co Did Not Meet Minimum Bid Price $1/Share
-SEC Filing 
SEC Filing  · 08/20 20:09
Histogen Shares Additional Emricasan Data From COVID-19 Study
Benzinga · 08/16 18:58
Histogen and Amerimmune Announce Additional Findings From Phase 1 Study Of Emricasan In Mild Symptomatic COVID-19 Patients; Says Emricasan Found To Have Statistically Significant Improvements In Clinically Relevant Hematological And Immune Markers
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and Immune Markers
Benzinga · 08/16 12:02
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression
GlobeNewswire · 08/16 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Conatus Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSTO stock price target is 2.700 with a high estimate of 3.000 and a low estimate of 2.400.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 3.73M
% Owned: 8.94%
Shares Outstanding: 41.73M
TypeInstitutionsShares
Increased
8
1.07M
New
7
448.76K
Decreased
3
183.25K
Sold Out
10
268.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
David Crean
President/Chief Executive Officer/Director
Richard Pascoe
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President/Secretary
Susan Knudson
Executive Vice President
Moya Daniels
Senior Vice President
Martin Latterich
Director
Steven Mento
Independent Director
Rochelle Fuhrmann
Independent Director
Jonathan Jackson
Independent Director
Daniel Kisner
Independent Director
Brian Satz
Independent Director
Susan Windham-bannister
No Data
About HSTO
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. It has a portfolio of product candidates derived from one core technology process that utilizes proteins and growth factors produced by hypoxia-induced multipotent cells, without using embryonic stem cells or animal components. The Company's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. HST 003 is a human extracellular matrix (hECM), a naturally secreted material, which is used for treatment of joint cartilage repair. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being jointly developed with its partner Amerimmune for the treatment of COVID-19.

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.